Research programme: ImmunoVEX vaccines - Amgen

Drug Profile

Research programme: ImmunoVEX vaccines - Amgen

Alternative Names: ImmunoVEX-based therapies programme

Latest Information Update: 19 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Viral infections
  • No development reported Human papillomavirus infections

Most Recent Events

  • 04 Mar 2011 BioVex has been acquired by Amgen
  • 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Vaccines pharmacodynamics section ,
  • 18 Jun 2002 Preclinical trials in Herpes simplex virus infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top